AnaptysBio, Inc. (ANAB) Misses Q2 EPS by 67c

AnaptysBio, Inc. (NASDAQ: ANAB) reported Q2 EPS of ($1.71), $0.67 worse than the analyst estimate of ($1.04). Revenue for the quarter came in at $10.97 million versus the consensus estimate of $22.76 million.

For earnings history and earnings-related data on AnaptysBio, Inc. (ANAB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 22nd Century Group files prospectus for warrant share resale
• Invesco Mortgage Capital declares $0.12 monthly dividend for June 2026